Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to $56,741.

  • Immuneering's Change in Account Payables fell 66.73% to $56,741 in Q4 2024 from the same period last year, while for Dec 2024 it was -$112,143, marking a year-over-year increase of 89.87%. This contributed to the annual value of -$112,143 for FY2024, which is 89.87% up from last year.
  • Latest data reveals that Immuneering reported Change in Account Payables of $56,741 as of Q4 2024, which was up 108.35% from -$679,454 recorded in Q3 2024.
  • In the past 5 years, Immuneering's Change in Account Payables ranged from a high of $1.1 million in Q3 2022 and a low of -$778,202 during Q3 2023.
  • Moreover, its 3-year median value for Change in Account Payables was $87,067 (2024), whereas its average is $45,098.
  • As far as peak fluctuations go, Immuneering's Change in Account Payables crashed by 731.07% in 2022, and later surged by 675.42% in 2024.
  • Quarterly analysis of 5 years shows Immuneering's Change in Account Payables stood at $274,072 in 2020, then tumbled by 262.37% to -$445,014 in 2021, then skyrocketed by 283.40% to $816,177 in 2022, then crashed by 79.10% to $170,568 in 2023, then slumped by 66.73% to $56,741 in 2024.
  • Its Change in Account Payables stands at $56,741 for Q4 2024, versus -$679,454 for Q3 2024 and $393,177 for Q2 2024.